June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Reduction of choroidal thickness was not associated with the outcomes of photodynamic therapy for pachychoroid spectrum diseases
Author Affiliations & Notes
  • norihiko misawa
    opthalmology, Osaka Shiritsu Daigaku, Osaka, Osaka, Japan
  • akika kyo
    opthalmology, Osaka Shiritsu Daigaku, Osaka, Osaka, Japan
  • kumiko hirayama
    opthalmology, Osaka Shiritsu Daigaku, Osaka, Osaka, Japan
  • Manabu Yamamoto
    opthalmology, Osaka Shiritsu Daigaku, Osaka, Osaka, Japan
  • michiko hirabayashi
    Shiraniwa Byoin, Ikoma, Nara, Japan
  • Takeya Kohno
    opthalmology, Osaka Shiritsu Daigaku, Osaka, Osaka, Japan
  • shigeru honda
    opthalmology, Osaka Shiritsu Daigaku, Osaka, Osaka, Japan
  • Footnotes
    Commercial Relationships   norihiko misawa, None; akika kyo, None; kumiko hirayama, None; Manabu Yamamoto, None; michiko hirabayashi, None; Takeya Kohno, None; shigeru honda, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 294. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      norihiko misawa, akika kyo, kumiko hirayama, Manabu Yamamoto, michiko hirabayashi, Takeya Kohno, shigeru honda; Reduction of choroidal thickness was not associated with the outcomes of photodynamic therapy for pachychoroid spectrum diseases. Invest. Ophthalmol. Vis. Sci. 2021;62(8):294.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : A reduction of choroidal thickness is generally thought to be associated with the outcomes of photodynamic therapy (PDT) for pachychoroid spectrum diseases (PSD). We performed a retrospective chart review to investigate whether the reduction of choroidal thickness after PDT may influence the visual and anatomical outcomes in PSD.

Methods : Fifty-three eyes of 53 patients (male 40, female 13) who underwent initial PDT were included in this study. Patients were diagnosed with pachychoroid neovasculopathy (PNV) (n= 20), polypoidal choroidal vasculopathy (PCV) (n=24) and central serous chorioretinopathy (CSC) (n=9). The subjects were divided into two groups according to the reduction ratio of central choroidal thickness (CCT) more than 15% (group A) or not (group B) at 3 months post-PDT. The best corrected visual acuity (BCVA), central retina thickness (CRT), and CCT were compared between the groups. For statistical analysis, each clinical factor was evaluated by paired or unpaired t-test where applicable between any two groups.

Results : The group A and group B contained 24 eyes and 29 eyes, respectively. The mean age, the baseline BCVA, CRT, CCT in the group A and group B were 68.0±13.2 vs 71.4±13.6 years, 0.25±0.29vs0.26±0.40(logMAR),301.0±117.0vs319.1±111.8μm and 310.0±111.9 vs 292.5±111.8μm, which showed no significant difference between the groups (P=0.39, 0.85, 0.57 and 0.57, respectively). No significant differences were observed in the post-PDT BCVA 0.18±0.32 vs 0.26±0.42(logMAR) (P=0.46) and post-PDT CRT 207.2±81.8 vs 237.8±102.9μm (P=0.24) between the group A and group B. A multiple regression analysis showed no significant variables associated with the reduction of CCT after PDT.

Conclusions : None of the pre-treatment BCVA, CCT, and CRT was associated with a reduction of CCT after PDT. The reduction of CCT was not associated with an improvement in visual acuity or CRT after the treatment. Decreased CCT might be a result, not a therapeutic role of PDT over the management of PSD.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×